EUVIMEDEUVIMED entdecken
Crossref

Preclinical Evidence for a Drug–Drug Interaction Between Cannabinol and Melatonin

Lyndsey L Anderson, Nicole A Hawkins, Ka Lai Yip, Michael Udoh iD, Jennifer A Kearney, Jonathon C Arnold

Basic & Clinical Pharmacology & Toxicology · 2025-01 · 136 (1)

DOI: 10.1111/bcpt.14120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 25.12.2024. Verfasst von Lyndsey L Anderson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Melatonin, Drug Interactions, Cytochrome P-450 CYP1A2, Cannabinol. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Barry and Joy Lambert.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The worldwide legalization of medicinal cannabis has led to an increased use of products made by commercial operators. These products often contain minor cannabinoids such as cannabinol (CBN) which are advertised to improve sleep. Products are also available in which CBN is combined with conventional therapies, with a common product containing both CBN and the widely used sleep‐aid melatonin. The combination of CBN and melatonin provides potential for a pharmacokinetic drug–drug interaction (DDI) given that cannabinoids are known to inhibit drug‐metabolizing enzymes. Indeed, we recently reported that CBN potently inhibited the CYP1A2‐mediated metabolism of caffeine. CYP1A2 is the major hepatic enzyme involved in the metabolism of melatonin; thus, in this study, we aimed to examine whether CBN inhibited CYP1A2‐mediated metabolism of melatonin in vitro and in vivo. We found CBN potently inhibited CYP1A2‐mediated metabolism of melatonin and increased the apparent oral bioavailability of melatonin in mice with a four‐fold increase in the plasma melatonin exposure. Our results provide an additional example of a potential DDI involving melatonin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelatoninDrug InteractionsCytochrome P-450 CYP1A2CannabinolBiological AvailabilityAnimalsMaleMiceHumansMicrosomes, LiverSleep Aids, PharmaceuticalCytochrome P-450 CYP1A2 InhibitorsMice, Inbred C57BLAdministration, Oral

Stichwörter der Autor:innen

CYP1A2cannabinoidcannabinolmelatoninmetabolism

Substanzen

MelatoninCytochrome P-450 CYP1A2CannabinolSleep Aids, PharmaceuticalCytochrome P-450 CYP1A2 InhibitorsCYP1A2 protein, human

Autor:innen und Institutionen

  • Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Michael Udoh

Förderung

  • Barry and Joy Lambert

Zitieren

APA

Anderson, L. L., Hawkins, N. A., Yip, K. L., Udoh, M., Kearney, J. A., & Arnold, J. C. (2025). Preclinical Evidence for a Drug–Drug Interaction Between Cannabinol and Melatonin. Basic & Clinical Pharmacology & Toxicology, 136(1). https://doi.org/10.1111/bcpt.14120

Vancouver

Anderson LL, Hawkins NA, Yip KL, Udoh M, Kearney JA, Arnold JC. Preclinical Evidence for a Drug–Drug Interaction Between Cannabinol and Melatonin. Basic & Clinical Pharmacology & Toxicology. 2025;136(1). doi:10.1111/bcpt.14120

BibTeX
@article{Anderson2025,
  author = {Anderson, Lyndsey L and Hawkins, Nicole A and Yip, Ka Lai and Udoh, Michael and Kearney, Jennifer A and Arnold, Jonathon C},
  title = {Preclinical Evidence for a Drug–Drug Interaction Between Cannabinol and Melatonin},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  volume = {136},
  number = {1},
  doi = {10.1111/bcpt.14120}
}
Kostenlos starten →